The FDA has approved Lembaz (adrabetadex), the first treatment shown to reduce the risk of death in patients with infantile onset Niemann-Pick disease type C (NPC), a rare inherited disease that causes progressive neurological decline.
Lembaz received Breakthrough Therapy designation. The FDA granted approval of Lembaz to Mandos, LLC, a subsidiary of Beren Therapeutics, PBC.
